Enrollment Complete for CUPID 2 PhaseIIbTrial with Results Expected in April 2015
Report Available for Download at http://www.lifesciadvisors.com/clients/celladon
"No currently available therapies for heart failure are able to stop or significantly modify the progression of heart failure.
The expression of the SERCA2a, orsarco/endoplasmic reticulum Ca2+-ATPase 2a, gene, is reduced in advanced heart failure, which adversely affects the contractility of the heart. Preclinical studies have demonstrated improvement in cardiac function after reintroduction of an additional copy of the gene. The Company has released positive results from the CUPID 1 Phase I/IIaclinical trial, finding a favorable safety profile, long-term expression of the SERCA2a transgene and, most importantly, a reduction in heart failure-related clinical events. Over the course of a 3 year follow-up, there was an 82% reduction in the rate of clinical events.
In a 41 page Initiation Report byLifeSciAdvisors, we explain the market potential for
Dr. McDonald's full Initiation Report is available to download at no cost at theLifeSciAdvisors website, www.lifesciadvisors.com. In addition to this Initiation Report,LifeSciAdvisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
TheLifeSciAdvisors research team is led by Dr.
LifeSciAdvisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSciAdvisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSciAdvisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release.LifeSciAdvisors disclaims, however, any intent or obligation to update these forward-looking statements.
Phone: (646) 597-6979
Vice President, Corporate Development and Investor Relations
Phone: (858) 432-7215